Impact of FDG-labelled positron emission tomography imaging on the management of non-small-cell lung cancer

Annals of Medicine

Volumn 33, Issue 6, 2001, Pages 404-409

  Salminen, E ^a   Mac Manus, M ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

FDG PET; Fluorodeoxyglucose; Non small cell lung cancer; Outcome; Staging; Treatment

Indexed keywords

FLUORODEOXYGLUCOSE;

ACCURACY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; LUNG NON SMALL CELL CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT PLANNING;

EID: 0034833797     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853890108995953     Document Type: Review

References (49)

1. Non-small-cell lung cancer - Stalemate or progress?
2. Risk of a new primary cancer among patients with lung cancer of different histological types
3. Survival of cancer patients in Finland 1955-1994
4. Lung cancer mortality in the Mayo Lung Project. Impact of extended follow-up
5. Screening for lung cancer. A critique of the Mayo Lung Project
6. Surgery for non-small cell lung cancer
7. Lymph node involvement, recurrence, and prognosis in resected small, peripheral, non-small cell lung carcinomas: Are these carcinomas candidates for video-assisted lobectomy?
8. Sites of recurrence in resected stage I non-small cell lung cancer. A guide for future studies
9. Recursive partitioning analysis of 1999 radiation therapy oncology group (RTOG) patients with locally advanced non small cell lung cancer: Identification of five groups with different survival
10. Chemotherapy in NSCLC: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
11. Radiotherapy for non-small-cell bronchial cancers: Definitions of volumes, patient selection. Recommendations of the International Association for the Study of Lung Cancer (IASLC)
12. Survival and prognosis following resection of primary non small cell bronchogenic carcinoma
13. Gross tumor volume is an independent predictor of survival in non-small cell lung carcinoma patients treated with conformal radiotherapy
14. Lung cancer proliferation correlates with F-18 Fluorodeoxyglucose uptake by positron emission tomography
15. Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer
16. Evaluation of fluorine-18-fluorodeoxyglucose whole body emision tomography imaging in the staging of lung cancer
17. Mediastinal lymph node staging of non-small-cell lung cancer: A prospective comparison of computed tomography and positron emission tomography
18. Comparitive efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer
19. Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s - Meta analytic comparison of PET and CT
20. Detection of extrathoracic metastases by positron emission tomography in lung cancer
21. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography
22. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non small cell lung cancer
23. FDG-PET imaging for the staging and follow-up of non small cell lung cancer
24. Roentgenographic evaluation of mediastinal nodes for preoperative assesment in lung cancer
25. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1cm), intermediate (1 to 3 cm) and large (>3 cm) lymph node lesions
26. How useful is positron emission tomography for lymphnode staging in non small cell lung cancer?
27. Metabolic staging of lung cancer
28. Preoperative staging of non-small-cell lung cancer with positron-emission tomography
29. The current status of positron emission tomography
30. High rate of detection of unsuspected metastases by PET in apparent stage III NSCLC: Implications for radical radiation therapy
31. FDG-PET staging in radical radiotherapy candidates with non-small cell lung cancer: Powerful correlation with survival and high impact on treatment
32. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: A prospective study
33. Image fusion of F-18 FDG PET and CT-is there a role in 3D-radiation treatment planning of non-small cell lung cancer?
34. The impact of 18 F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer
35. Positron emission tomography in thoracic radiography
36. Imaging with F-18 FDG PET is superior to T1-201 SPECT in the staging of non small-cell lung cancer for radical radiation therapy
37. Staging by positron emission tomography predicts survival in patients with non small cell lung cancer
38. Measurement of clinical and subclinical tumour response using FDG and PET: Review and 1999 EORTC recommendations
39. Early F-18 FDG-PET response to radical chemoradiotherapy correlates strongly with survival in unresectable non-small cell lung cancer
40. Decision tree sensitivity analysis for cost-effectiveness of chest FDG-PET in patients with a pulmonary tumour (NSCLC)
41. Reimbursement and technology assessment for positron imaging
42. Decision tree sensitivity analysis for cost effectiveness of FDG-PET in the staging and management of non-small cell lung carcinoma
43. Lung cancer and positron emission tomography with fluorodeoxyglucose
44. Randomized controlled trial to evaluate the cost effectiveness of positron emission tomography (PET) added to conventional diagnosis in non-small cell lung cancer
45. Being equipped for clinical PET
46. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases
47. A combined PET/CT scanner for clinical oncology